Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHMP Delays Review of Portola's Ondexxya; Who Will Pass Muster?

Executive Summary

With its final meeting of the year under way, the EMA's medicines evaluation committee, the CHMP, will bring seasonal cheer for some companies if it decides their products merit EU approval. New treatments from Shionogi and Medac are up for an opinion. A planned appearance by Portola before the panel to answers questions relating to its marketing application for Ondexxya/AndexXa has been cancelled and the review period for the marketing authorization application for the product extended.

Related Content

New Filings At The EMA
Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations
Moment Of Truth For Pacritinib And Other EU Approval Hopefuls
Eight Things To Know From Novartis' Third Quarter Call
EMA Acts On Patient Concerns Over Fluoroquinolone Antibiotics
Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands
Companies Reveal Likely EU Review Outcomes Against EMA Advice
EMA Strengthens Warnings For Retinoids, Starts Probe Into Omega-3 Fatty Acid Medicines
AZ Sees A Future For Forxiga In Type 1 Diabetes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts